Sandoz Group AG (SDZXF OTCQX) stock market data APIs
$60.421
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
Sandoz Group AG Financial Data Overview
Price chart is built with
Anychart
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Prev. Close
60.421
Open
60.421
High
60.421
Low
60.421
52 wk Range
35.9687-62.57
Market Cap
25 876 M
P/E Ratio
115.5337
Shares Outstanding
431 M
Revenue
10 587 M
EPS
1.22
Dividends (Yield)
0.011
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sandoz Group AG data using free add-ons & libraries
Get Sandoz Group AG Fundamental Data
Sandoz Group AG Fundamental data includes:
- Net Revenue: 10 587 M
- EBITDA: 1 023 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sandoz Group AG News
New
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to valu...
Regeneron settles patent dispute with Sandoz over Eylea biosimilar
[Intellectual Property] stocknshares Sandoz (OTCQX:SDZNY [https://seekingalpha.com/symbol/SDZNY]) announced on Tuesday that Regeneron (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) has agreed t...
Health Care Roundup: Market Talk
0809 GMT – Novartis’s $1.4 billion deal to buy Tourmaline Bio looks like a strategically meaningful move that is set to complement its cardiovascular-treatment pipeline, Vontobel analyst Stefan Sc...
Should Sandoz Group’s Generic Rivaroxaban Launch in Germany Matter to SWX:SDZ Investors?
Sandoz announced the launch of generic rivaroxaban in Germany in August 2025, introducing new generic strengths of 10 mg, 15 mg, and 20 mg after the dosage patent was revoked, following their legal ch...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
